MannKind Company Profile (NASDAQ:MNKD)

About MannKind (MNKD)

MannKind logoMannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MNKD
  • CUSIP: 56400P20
Key Metrics:
  • Previous Close: $0.90
  • 50 Day Moving Average: $1.65
  • 200 Day Moving Average: $0.86
  • 52-Week Range: $0.85 - $8.50
  • Trailing P/E Ratio: 0.66
  • Foreward P/E Ratio: -0.98
  • P/E Growth: -0.05
  • Market Cap: $86.20M
  • Outstanding Shares: 95,776,000
  • Beta: 3.26
  • Return on Equity: -15.95%
  • Return on Assets: 46.57%
  • Debt-to-Equity Ratio: -0.62%
  • Current Ratio: 0.46%
  • Quick Ratio: 0.41%

Analyst Ratings

Consensus Ratings for MannKind (NASDAQ:MNKD) (?)
Ratings Breakdown: 3 Sell Ratings, 1 Hold Rating
Consensus Rating:Sell (Score: 1.25)
Consensus Price Target: $0.32 (64.81% downside)

Analysts' Ratings History for MannKind (NASDAQ:MNKD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/28/2017Piper Jaffray CompaniesReiterated RatingUnderweightN/AView Rating Details
11/11/2016JPMorgan Chase & Co.Reiterated RatingUnderweightN/AView Rating Details
8/31/2016S&P Equity ResearchLower Price Target$0.84 -> $0.70N/AView Rating Details
6/1/2016Royal Bank of CanadaLower Price TargetUnderperform$1.00 -> $0.15N/AView Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
4/1/2016Goldman Sachs Group IncReiterated RatingSellN/AView Rating Details
1/6/2016Griffin SecuritiesUpgradeNeutral -> Buy$4.00N/AView Rating Details
11/14/2015Jefferies Group LLCReiterated RatingBuy$9.00N/AView Rating Details
5/11/2015MLV & Co.Lower Price TargetHold$7.00 -> $4.00N/AView Rating Details
(Data available from 4/24/2015 forward)


Earnings History for MannKind (NASDAQ:MNKD)
Earnings by Quarter for MannKind (NASDAQ:MNKD)
Earnings History by Quarter for MannKind (NASDAQ:MNKD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2017Q4 2016($0.20)($0.19)$6.00 million$12.40 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.06)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)$5.40 millionViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.09($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.11)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MannKind (NASDAQ:MNKD)
Current Year EPS Consensus Estimate: $-0.87 EPS
Next Year EPS Consensus Estimate: $-0.92 EPS


Dividend History for MannKind (NASDAQ:MNKD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for MannKind (NASDAQ:MNKD)
Insider Ownership Percentage: 0.94%
Institutional Ownership Percentage: 19.71%
Insider Trades by Quarter for MannKind (NASDAQ:MNKD)
Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)
Insider Trades by Quarter for MannKind (NASDAQ:MNKD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.00View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.00View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.00View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.12View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for MannKind (NASDAQ:MNKD)
Latest Headlines for MannKind (NASDAQ:MNKD)
DateHeadline logo$0.12 EPS Expected for MannKind Co. (MNKD) This Quarter - April 25 at 12:26 AM logoMannKind (MNKD) Earns Coverage Optimism Score of 0.09 - April 21 at 9:54 PM logoMannKind Co. (MNKD) Short Interest Update - April 19 at 6:56 PM logoBRIEF-Mannkind's unit entered exchange agreement - April 19 at 10:31 AM logoSomewhat Positive Press Coverage Very Likely to Impact MannKind (MNKD) Share Price - April 18 at 6:05 PM logoVery Favorable News Coverage Very Likely to Impact MannKind (MNKD) Share Price - April 14 at 10:54 AM logoIs MannKind Corporation Getting Ready to Sell? - April 10 at 4:50 PM logoConatus Pharmaceuticals and MannKind Look Forward to Promoting Their Brand - April 3 at 10:12 AM logoShort Interest in MannKind Co. (MNKD) Declines By 5.9% - March 27 at 7:47 AM logoMANNKIND CORP Financials - March 23 at 7:07 PM logoBillionaires' Worst Healthcare Stock Picks for 2017 (So Far) - March 22 at 9:25 AM logoCould MannKind Corporation's Marketing Blitz Pay Off? - March 21 at 4:25 PM logoJefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now - March 20 at 10:12 AM logoEdited Transcript of MNKD earnings conference call or presentation 16-Mar-17 9:00pm GMT - March 17 at 6:45 PM logoMANNKIND CORP Files SEC form 8-K, Other Events - March 17 at 6:45 PM logoMannKind Co. (MNKD) Issues Quarterly Earnings Results - March 16 at 10:21 PM logo10-K: MANNKIND CORP - March 16 at 7:19 PM logoMannKind Corporation Reports 2016 Fourth Quarter and Full Year Financial Results - March 16 at 7:19 PM logoMANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 16 at 7:19 PM logoMannKind beats by $0.76, beats on revenue - March 16 at 5:42 PM logoQ4 2016 MannKind Corp Earnings Release - Before Market Open - March 16 at 9:14 AM logoMannKind's (MNKD) CEO Matt Pfeffer Presents At 29th Annual ROTH Conference (Transcript) - Seeking Alpha - March 15 at 6:47 PM logoBetter Buy: MannKind Corp. vs. Dexcom -- The Motley Fool - Motley Fool - March 11 at 8:03 AM logoMannKind Needs To Boost Script Sales - Will A Television Show Help? - Seeking Alpha - March 11 at 8:03 AM logoMannKind Co. (MNKD) Sees Significant Growth in Short Interest - March 10 at 11:04 AM logoBetter Buy: MannKind Corp. vs. Dexcom - March 9 at 10:27 AM logoMannKind Corporation and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes - March 8 at 10:01 AM logoHere's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February - March 7 at 1:17 PM logoMannKind Corporation Announces Upcoming Events - March 7 at 10:22 AM logoReverse split gets company compliant with Nasdaq. - Seeking Alpha - March 3 at 6:37 PM logoMannKind Corporation (MNKD) Stock Sinks on Reverse Stock Split Plans - March 3 at 5:21 PM logoWhy MannKind Corporation Stock Is Sinking Today - March 3 at 12:21 PM logoPost-split trading in MannKind commences today - March 3 at 10:10 AM logoMANNKIND CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matt - March 2 at 9:29 AM logoCan MannKind Be Saved? - February 27 at 6:04 PM logoMANNKIND CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets - February 23 at 6:40 PM logoNotable Wednesday Option Activity: AAWW, MNKD, TREX - February 22 at 6:44 PM logoMannKind Receives $16.7 Million From Sale of Valencia Property - February 21 at 6:21 PM logo9:03 am Mannkind receives $16.7 mln upon closing the sale of real estate owned by the co in Valencia, California, net of closing costs - February 21 at 6:21 PM logoMannKind - Afrezza Sales Slip As New Sales Force Starts - Seeking Alpha - February 19 at 5:40 PM logoMannKind, Afrezza Sales, And 'Free Beer Tomorrow' - Seeking Alpha - February 11 at 6:42 PM logoHere's Why MannKind Corporation Rose 11.5% in January - Motley Fool - February 7 at 7:38 AM logoHere's Why MannKind Corporation Rose 11.5% in January - February 6 at 10:11 AM logoMannKind: The Saga Of Smoking Guns - February 3 at 7:18 PM logoForm 5 MANNKIND CORP For: Dec 31 Filed by: KRESA KENT - February 3 at 5:28 AM logoGood News and Bad News for MannKind Corporation - February 2 at 7:25 PM logoMannkind in Free Fall After Changes to Insulin Product, Sales Force - February 2 at 7:25 PM logoHere's Why MannKind Corporation Is Plunging - February 2 at 7:25 PM logoMannKind Looks to Boost Flagging Afrezza Sales - February 2 at 7:25 PM logoMannKind refines commercial approach for Afrezza; reverse stock split proposed; shares down 16% - February 2 at 1:19 PM


Frequently Asked Questions for MannKind (NASDAQ:MNKD)

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) announced its earnings results on Thursday, March, 16th. The company reported ($0.19) EPS for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.01. The company earned $12.40 million during the quarter, compared to the consensus estimate of $6 million. MannKind's revenue for the quarter was up NaN% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.30) earnings per share.

When will MannKind make its next earnings announcement?

MannKind is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

Where is MannKind's stock going? Where will MannKind's stock price be in 2017?

4 analysts have issued 12 month target prices for MannKind's shares. Their forecasts range from $0.10 to $0.70. On average, they expect MannKind's share price to reach $0.32 in the next year.

Are investors shorting MannKind?

MannKind saw a decline in short interest in March. As of March 31st, there was short interest totalling 19,490,324 shares, a decline of 1.5% from the March 15th total of 19,793,968 shares. Based on an average trading volume of 1,796,589 shares, the days-to-cover ratio is presently 10.8 days.

Who owns MannKind stock?

MannKind's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FLYNN JAMES E (5.17%). Company insiders that own MannKind stock include Hakan Edstrom, Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya.

How do I buy MannKind stock?

Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of MannKind stock cost?

One share of MannKind stock can currently be purchased for approximately $0.90.

MannKind (MNKD) Chart for Monday, April, 24, 2017

This page was last updated on 4/24/2017 by Staff